Board summary
Key figures
70,346
Registered population
60.1% aged 18–64
18.7%
Aged 65+
ICB 19.0% · England 17.9%
5.8%
Ethnic minority (non-White)
2.3% Asian · England 9.6%
46.3%
In IMD quintile 1
ICB 31.9% · England 21.0%
~30,342
Core20 residents (est.)
Resident basis; registered basis ~31,813 · see page 3
12,340
Hypertension register
+5.75% in 3 yrs · England +5.60%
741
SMI register
37.8% of Knowsley (LAD)'s
2,245
COPD register
Reviews +17.23% in 3 yrs
Forecast to 2030
14,312
Hypertension patients, 2030
+1,972 on today
71.3%
QRISK ≥20% on statins, 2030
+2.29pp over 3 yrs
5.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Learning disability and COPD registers contracted.
From 2023 to 2025, learning disability (-3.5% vs England +5.4%) and COPD (-3.4% vs +2.6%) prevalence fell, which may reflect unverified coding gaps.
Pre-school MMR and asthma reviews trail.
Age-5 MMR dose 2 is 80.4% (below the 95.0% target by 14.6 pp) and asthma reviews reach 63.2% (England 65.7%; 1,673 unreviewed).
Adult blood pressure, COPD and screening.
Hypertension control reaches 72.3% (England 70.3%), alongside 77.6% COPD annual reviews (England 76.4%) and 72.5% cervical screening (England 66.8%).
Population, age and ethnicity
Registered list of 70,346 has higher child and older cohorts than England
Knowsley Central and South PCN covers 70,346 registered patients across member practices. Children aged 0-17 comprise 21.1% (14,859 patients), in line with Knowsley LAD (21.1%) and above NHS Cheshire and Merseyside ICB (19.2%) and England (19.6%). Patients aged 65+ represent 18.7% (13,186 patients), above the LAD (16.9%), below the ICB (19.0%), and above England (17.9%). Census usual residents are 94.2% White (LAD 95.3%, ICB 93.0%, England 81.1%), with a 5.8% ethnic minority share; these area figures do not reflect registered-patient ethnicity. Projected list growth is 2.8% to 2030 via an unverified model.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Knowsley (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Knowsley LA) | 2,784 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.8% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Knowsley LA) | 1,440 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Knowsley LA) | 23.1 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 46.3% PCN-wide but spans a 70.2 pp practice range
Across the PCN, Core20 share is 46.3% (average IMD decile 3.9), below Knowsley (52.5%) but above the ICB (31.9%) and England (21.0%). Practice rates span 70.2 pp, from 17.4% at Roby Medical Centre to 87.6% at Stockbridge Village Hc. Modelled practice rates weight to 45.2%, a 1.05 pp discrepancy versus the PCN rate. Stockbridge Village Hc has the highest share (87.6%) and estimated volume (7,488 patients), followed by Dinas Lane Medical Centre (53.3%, 5,432 patients). Addressing both high-concentration practices and large-volume cohorts requires differentiated outreach.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
741
SMI register
1.08% recorded prevalence
445
Learning disability register
0.65% recorded prevalence
32
Care homes, 1,380 beds
In the PCN catchment
11.5%
Provide unpaid care
Knowsley (LAD), Census 2021
The PCN records 741 severe mental illness patients (1.1%, England 1.0%) and 445 learning disability patients (0.7%, England 0.6%), alongside 32 catchment care homes (1,380 beds). Knowsley LAD has an 11.5% unpaid care rate and 14 rough sleepers, which cannot be extrapolated to GP lists. Recorded SMI and learning disability prevalence exceed national rates, but crude prevalence does not establish unmet need or care home resident caseloads.
Severe mental illness: physical health checks
SMI recorded prevalence is 1.1% (England 1.0%). Annual blood pressure checks reach 84.9% (England 83.4%) and BMI recording reaches 85.5% (England 82.1%, Knowsley 89.8%). Missing health check elements are uncaptured, so completed comprehensive checks cannot be inferred.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
12,340
Hypertension register
+5.75%
Register growth, 3 yrs
Knowsley (LAD) +5.44% · England +5.60%
+4.74pp
BP control, under 80
≤140/90 · +4.30pp aged 80+
+1,972
More patients by 2030
Forecast 14,312 (20.04%)
Hypertension case-finding and control
Recorded hypertension prevalence is 17.9% (12,340 patients), above England (15.2%), Knowsley (16.7%) and the ICB (16.8%), though crude QOF rates do not confirm case-finding completeness and the implied base differs from the registered list of 70,346. Annual blood pressure monitoring reached 90.5% (England 90.0%), and patients treated to target reached 72.3% (England 70.3%, ICB 69.1%). Control in patients aged under 80 reached 69.5% (England 67.8%), while three-year prevalence rose +5.8% (England +5.6%). Unverified projections indicate register demand could reach 14,312 patients by 2030, an addition of 1,972 patients. Strong blood pressure control above national rates protects cardiovascular outcomes, though managing an expanding cohort will require sustained clinical capacity.
Lipids and statins
While QRISK ≥20% lipid therapy coverage reaches 66.4% (England 63.6%), three-year growth rose only +3.6% against +6.2% in England. Secondary-prevention diabetes statin therapy fell 0.4% (England +1.0%). Trailing therapy growth behind national rates highlights an opportunity to review recall protocols for high-risk patients.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 152,574 | £1.70 | £1.71 | £1.86 | £259,376 |
| Cardiovascular (all), 2025 | 211,272 | £4.52 | £4.37 | £3.33 | £954,949 |
In 2026, lipid-regulating drugs cost £1.70 per item across 152,574 items (annual spend £259,376), compared with £1.86 in England, £1.63 in Knowsley (LAD), and £1.71 in the ICB, representing £24,412 less than at England's unit cost. Lower unit cost than England could reflect local formulary choices, providing an opportunity to expand lipid therapy coverage without disproportionate expenditure.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+16.72%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.53%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 3.3% (England 1.9%), though its register fell 3.4% over three years (England +2.6%), while COPD reviews reach 77.6% (England 76.4%). Asthma prevalence is 7.1% (England 6.6%, 4,542 patients), but annual reviews trail England at 63.2% (England 65.7%), leaving an estimated 1,673 unreviewed patients. Paediatric asthma prescribing reaches 2,939 items per 1,000 aged 5-19, well above England (1,488). High prescribing alongside lower review completion may reflect unverified recall gaps testable by clinical audit.
Cancer register and children's immunisation
The cancer register records 3,017 patients (4.4% prevalence vs England 3.8%). In childhood immunisations, MMR dose 2 coverage at age 5 reaches 80.4% (ICB 84.4%, England 82.8%), trailing the 95.0% target by 14.6 pp, with a 10.1 pp drop from dose 1 (90.5%). At 24 months, 6-in-1 coverage is 85.5% (England 92.2%). Slower second-dose completion leaves cohort immunity vulnerable and warrants systematic call-recall follow-up.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of cancers with a known stage in NHS Cheshire and Merseyside ICB (7,482 of 13,490) were diagnosed at stage 1 or 2 (England 55.3%), a distance of -19.5 pp to the 75.0% national ambition by 2028, requiring about 2,640 extra early-stage cases annually. Known-stage share was 72.8% (13,490 of 18,522 cancers; England 67.0%). In the PCN, cancer prevalence is 4.4% (3,017 patients), with three-year growth of +7.7% (England +9.0%). Cervical screening reaches 72.5% (England 66.8%) and breast screening reaches 72.4% (England 69.9%). Staging describes the ICB system, not PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Mersey and West Lancashire Teaching Hospitals NHS Trust, 77.9596% of patients met the 62-day referral to treatment standard against the 85.0% standard (distance -7.0 pp; ICB 76.232%, distance -8.8 pp). For the 28-day faster diagnosis standard, the trust achieved 72.3923% against the 75.0% standard (distance -2.6 pp; ICB 77.2451%, distance 2.2 pp). On the 31-day combined treatment standard, the trust reached 95.4621% against the 96.0% standard (distance -0.5 pp; ICB 95.7087%, distance -0.3 pp). These hospital figures reflect acute provider flow rather than PCN referral performance.
| Pathways within standard (%) | Mersey and West Lancashire | Liverpool | North Cheshire and Mersey | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 72.39 | 75.47 | 80.21 | 77.25 | 79.32 |
| 31-day treatment (96%) | 95.46 | 90.51 | 98.17 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 77.96 | 73.26 | 83.67 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Mersey and West Lancashire | Liverpool | North Cheshire and Mersey | England |
|---|---|---|---|---|
| MRI | 14.04 | 6.42 | 0.53 | 21.40 |
| CT | 13.08 | 0.71 | 2.32 | 9.92 |
| Echocardiography | 34.88 | 12.55 | 28.04 | 28.48 |
| Colonoscopy | 18.04 | 33.14 | 15.98 | 30.83 |
| Gastroscopy | 18.17 | 44.99 | 20.24 | 29.02 |
| All 15 DM01 tests | 21.17 | 11.50 | 6.34 | 23.14 |
| Community services activity | Knowsley residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 45,655 | 541,280 |
| Referrals | 8,475 | 97,150 |
| Patients with a contact | 12,490 | 146,240 |
Community services (residents of Knowsley), Jun 2026 (provisional). In the provisional Jun 2026 Community Services Dataset, adults aged 65 and over accounted for 57.9% of contacts among Knowsley borough residents (26,435 of 45,655 total contacts). These data reflect borough-level community activity and cannot be attributed directly to PCN registered patients.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Roby | 106 | 17.4 | 87.4% | 82.7% | 95.9% |
| Tarbock | 111 | 34.6 | 85.0% | 58.8% | 93.3% |
| Cedar Cross | 123 | 41.8 | 63.4% | 75.7% | 89.7% |
| Nutgrove Villa | 128 | 63.8 | 89.0% | 73.7% | 89.6% |
| Prescot | 111 | 28.1 | 87.5% | 77.0% | 86.2% |
| Dr M Suares' | 111 | 36.4 | 67.6% | 75.0% | 84.5% |
| Longview | 87 | 87.2 | 70.6% | 78.2% | 83.1% |
| Hollies | 114 | 25.5 | 54.8% | 73.5% | 77.2% |
| Stockbridge | 110 | 87.6 | 31.9% | 74.8% | 73.6% |
| Dinas Lane | 96 | 53.3 | 27.7% | 81.2% | 73.4% |
| Park House | 108 | 28.9 | 32.0% | 71.1% | 69.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eight of 25 measures lag England over three years despite strong review gains
Eight of 25 compared measures trail England over three years. The widest relative lags appear in recorded disease prevalence: three-year register change was -3.5% for learning disability (England +5.4%, Knowsley LAD -0.8%) and -3.4% for COPD (England +2.6%, Knowsley LAD -2.7%). QRISK ≥ 20% lipid therapy growth (+3.6% vs England +6.2%) and dementia growth (+3.4% vs England +6.0%, Knowsley LAD +11.5%) also trailed. In contrast, annual reviews improved: 12-month COPD reviews rose +17.2% (England +2.8%) and asthma reviews grew +16.7% (England +4.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
COPD register
QRISK statin treatment
Dementia register
Diabetes statin (CVD)
COPD reviews
Asthma reviews
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Knowsley (LAD) | Asset | PCN | Knowsley (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 32 (1,380 beds) | n/a | Schools (catchment) | 117 | n/a |
| Children's centres | 10 | 15 | Places of worship | 37 | 48 |
| Libraries | 4 | 3 | Primary schools (LA maintained) | 24 | 32 |
| Primary academies | 12 | 13 | Special schools | 1 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma review and prescribing recall
Annual asthma reviews reach 63.2% against 65.7% in England across a 4,542-patient register, leaving an estimated 1,673 patients without a recorded review in 12 months. For discussion: practices could run a single-template asthma recall audit prioritising unreviewed patients and reviewing inhaler prescribing alongside after-school review slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
COPD and learning disability register audit
Over 2023 to 2025, COPD prevalence fell 3.4% (England +2.6%; modelled gap -912 to +271 patients) and learning disability fell 3.5% (England +5.4%; gap -32 to +29). For discussion: practices could audit clinical records for patients with repeated respiratory prescribing or historical learning disability codes missing from active QOF registers. Low cost, quick to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Pre-school MMR second dose recall
Age-5 MMR dose 2 coverage in Q1 2025/26 is 80.4% (ICB 84.4%, England 82.8%; cohort 189), 14.6 pp below the 95.0% target and 10.1 pp below dose 1 (90.5%). For discussion: practices could run targeted call-recall audits for children due their second MMR dose and offer flexible clinic times. Moderate effort to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric primary care capacity review (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Two-track Core20 allocation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI health check review (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Sustain hypertension control pathways (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| MMR second dose recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Sustain screening coverage (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Asthma review and prescribing recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · COPD and learning disability register audit (p12) | COPD register · COPD: QOF prevalence · Learning disability register | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Option 3 · Pre-school MMR second dose recall (p12) | MMR dose 2 coverage at age 5 · MMR dose 1 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
